Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Operations (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Cash from Operations for 6 consecutive years, with 44865000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 22.47% to 44865000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 235455000.0 through Dec 2025, up 5.48% year-over-year, with the annual reading at 235455000.0 for FY2025, 5.48% up from the prior year.
  • Cash from Operations for Q4 2025 was 44865000.0 at Relay Therapeutics, up from 62119000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 46640000.0 in Q1 2021, with the low at 89188000.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 54438700.0, with a median of 57480500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations skyrocketed 308.83% in 2021, then plummeted 205.43% in 2022.
  • Over 5 years, Cash from Operations stood at 39707000.0 in 2021, then crashed by 43.75% to 57079000.0 in 2022, then crashed by 56.25% to 89188000.0 in 2023, then soared by 35.12% to 57868000.0 in 2024, then increased by 22.47% to 44865000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 44865000.0, 62119000.0, and 55261000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.